Collegium Pharmaceutical Inc (COLL)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 172,542 | 159,072 | 34,366 | 17,640 | 56,464 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 228,842 | 195,431 | 194,842 | 202,928 | 186,031 |
| Return on total capital | 75.40% | 81.40% | 17.64% | 8.69% | 30.35% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $172,542K ÷ ($—K + $228,842K)
= 75.40%
Collegium Pharmaceutical Inc's return on total capital has shown fluctuations over the years. In December 31, 2020, the return on total capital was relatively high at 30.35%, indicating the company was efficient in generating returns from its capital investments. However, by December 31, 2021, the return dropped to 8.69%, which could suggest a decrease in profitability or lower efficiency in capital utilization.
In the following years, Collegium Pharmaceutical Inc's return on total capital improved, reaching 17.64% by December 31, 2022. This indicates a recovery in the company's ability to generate returns compared to the previous year. Subsequently, the return on total capital surged to 81.40% by December 31, 2023, showing a significant increase in profitability and efficient capital management.
By December 31, 2024, Collegium Pharmaceutical Inc maintained a high return on total capital of 75.40%, demonstrating continued strong performance in generating returns relative to the capital invested. Overall, the fluctuation in return on total capital over the years suggests varying levels of efficiency and profitability in utilizing the company's capital resources.
Peer comparison
Dec 31, 2024